Pure Global
NCT02298738

Effect of Vit D on New-onset AF in Hypertension

Relation of Low Vitamin D Levels and New-onset AF Among Hypertensive Patients
Ankara University·ClinicalTrials.govCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Fibrillation,Hypertension
Study type
Observational
Sponsor & location
Primary sponsor
Ankara University
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2012
End date
Nov 01, 2014
Enrollment
227 participants
Primary outcome

hypovitaminosis D

Summary

Atrial fibrillation (AF), an important cause of cardiac mortality and morbidity is the most
 common type of cardiac arrhythmia in clinical practice. Hypertensive individuals are at
 particular risk of development of atrial fibrillation. Renin-angiotensin-aldosteron system
 (RAS) which is activated in hypertension may be the underlying mechanism of AF among
 hypertensive patients.
 
 Vitamin D deficiency has been shown to be involved in the pathogenesis of hypertension,
 cardiovascular disease and obesity. Increased RAS activity is one of the postulated
 mechanisms by which vitamin D deficiency may trigger the development of hypertension and
 various cardiovascular diseases. On the basis of these data we hypothesized that
 hypovitaminosis D might be associated with new-onset AF among patients with hypertension.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02298738
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02298738 through Pure Global AI's free database. This phase not specified trial is sponsored by Ankara University and is currently Completed. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 227 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.